<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00597480</url>
  </required_header>
  <id_info>
    <org_study_id>P070303</org_study_id>
    <nct_id>NCT00597480</nct_id>
  </id_info>
  <brief_title>Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)</brief_title>
  <acronym>SGA</acronym>
  <official_title>Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH) by Comparison of Two Regimens of rhGH Administration to SGA Children. Pharmacogenetics of Metabolic Responses to rhGH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recombinant growth hormone (rhGH) treatment is widely used in France to normalize height&#xD;
      during childhood and final height in children born small for gestational age (SGA). Because&#xD;
      rhGH has been associated with increased insulin levels and insulin resistance, concern has&#xD;
      been expressed regarding the late consequences of rhGH treatment on risk factors for diabetes&#xD;
      mellitus type II and metabolic syndrome, especially in possibly predisposed subjects as SGA&#xD;
      children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recombinant growth hormone (rhGH) treatment is widely used in France to normalize height&#xD;
      during childhood and final height in children born small for gestational age (SGA). Because&#xD;
      rhGH has been associated with increased insulin levels and insulin resistance, concern has&#xD;
      been expressed regarding the late consequences of rhGH treatment on risk factors for diabetes&#xD;
      mellitus type II and metabolic syndrome, especially in possibly predisposed subjects as SGA&#xD;
      children.&#xD;
&#xD;
      Because rhGH use in this population will sharply increase in the coming years, our purpose is&#xD;
      to identify and analyze factors that predispose these children born SGA to the metabolic&#xD;
      consequences of rhGH therapy.&#xD;
&#xD;
      The main objective of this study is to identify and analyze factors implicated in the&#xD;
      variability of the metabolic and growth responses to rhGH treatment in children born SGA. We&#xD;
      want to:&#xD;
&#xD;
        -  Quantify the metabolic effects of rhGH treatment by analyzing insulin levels, insulin&#xD;
           sensitivity and lipid profile (lipolysis and ketogenesis);&#xD;
&#xD;
        -  Evaluate the effects of two different rhGH regimens on the growth of children born SGA;&#xD;
&#xD;
        -  Determine if the metabolic effects of rhGH therapy correlate to the growth responses in&#xD;
           the two groups;&#xD;
&#xD;
        -  Identify factors, especially genetic factors, responsible for the variations in&#xD;
           individual metabolic and growth-promoting effects of rhGH in children born SGA.&#xD;
&#xD;
      This is a randomized, open-labeled, 2-year study, which will compare two regimens of rhGH&#xD;
      therapy on the growth responses and metabolic effects in short children born SGA.&#xD;
&#xD;
      100 prepubertal, non GH deficient, short children (height &lt; -3 SDS) born SGA (birth height &lt;&#xD;
      -2 SDS) will be randomized to receive either the recommended dose in the EU of rhGH&#xD;
      (Norditropine SimpleXx®), or the dose to achieve a &quot;treat-to target&quot; value of IGF-1 levels&#xD;
      within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day) for 24 months.&#xD;
&#xD;
      Metabolic effects of rhGH treatment will be evaluated by body mass index (BMI), fasting&#xD;
      insulin and glucose levels, HOMA index of insulin resistance, insulin and glucose levels&#xD;
      during OGTT, HbA1C and fasting serum lipids (free fatty acids, 3-hydroxybutyrate, total&#xD;
      cholesterol, LDL and HDL cholesterol, triglycerides). Height, growth velocity, IGF-1 and&#xD;
      IGF-BP3 levels will evaluate growth response of rhGH treatment.&#xD;
&#xD;
      Polymorphisms of different genes of the signaling pathway of GH and insulin will be analyzed&#xD;
      in order to search for those possibly responsible for the variability in metabolic and growth&#xD;
      responses during rhGH treatment in SGA children.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    no more inclusions&#xD;
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identify and analyze factors implicated in the variability of the metabolic and growth responses to rhGH treatment in children born SGA</measure>
    <time_frame>every three months during twenty seven months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic effects of rhGH treatment will be evaluated by body mass index (BMI)</measure>
    <time_frame>every three months during</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polymorphisms of different genes of the signaling pathway of GH and insulin</measure>
    <time_frame>the day of inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Small for Gestational Age</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the recommended dose in the EU of rhGH (Norditropine SimpleXx®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the dose to achieve a &quot;treat-to target&quot; value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhGH (Norditropine SimpleXx®)</intervention_name>
    <description>the recommended dose in the EU of rhGH (Norditropine SimpleXx®</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhGH norditropine simple Xx</intervention_name>
    <description>the dose to achieve a &quot;treat-to target&quot; value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prepubertal age&#xD;
&#xD;
          -  Prepubertal characteristics&#xD;
&#xD;
          -  Non GH deficient&#xD;
&#xD;
          -  Short children (height &lt; -2.5 SDS)&#xD;
&#xD;
          -  Born SGA (birth height &lt; -2 SDS)&#xD;
&#xD;
          -  Parental height adjusted (&lt; -1 DS)&#xD;
&#xD;
          -  No rhGH treatment before inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ALLERY to rhGH or excipients&#xD;
&#xD;
          -  Small height etiologies&#xD;
&#xD;
          -  Cancer or cancer treatment ongoing&#xD;
&#xD;
          -  Drugs interference with growth&#xD;
&#xD;
          -  Mental impairment&#xD;
&#xD;
          -  Hypertrophic cardiopathy impairment&#xD;
&#xD;
          -  Hypertension not under controlled&#xD;
&#xD;
          -  Intra cranial hypertension not controlled&#xD;
&#xD;
          -  Diabetes and hyperglycaemia without diabetes&#xD;
&#xD;
          -  Dyslipidemia&#xD;
&#xD;
          -  Hepatitis&#xD;
&#xD;
          -  Kidney failure&#xD;
&#xD;
          -  Chromosomic aberration and/or genetic disorders (except Silver Russel Syndrome)&#xD;
&#xD;
          -  No social security&#xD;
&#xD;
          -  State of health in worst conditions after cardiac surgery, polytraumatism&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cecile Teinturier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Saint Vincent de Paul</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>January 7, 2008</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2008</study_first_posted>
  <last_update_submitted>April 20, 2015</last_update_submitted>
  <last_update_submitted_qc>April 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Growth hormone</keyword>
  <keyword>Child</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>metabolic syndrome X</keyword>
  <keyword>children born small for gestational age</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

